August 19, 2024 – New York, NY: BranchLab has appointed Errol Taylor to its Board of Advisors to help guide the newly launched company on its mission to reimagine healthcare advertising within the changing privacy standards that govern it. As the former Head of BioPharma Practice at Milbank, Taylor is a distinguished biopharmaceutical legal advisor with decades of expertise in intellectual property, product lifecycle management, complex technology protection, licensing, and other transactions.  

Taylor’s deep understanding of complex legal frameworks will help BranchLab navigate the evolving landscape of healthcare advertising, ensuring its solutions are both effective and compliant. BranchLab has created an “ID-less” solution for bridging the gap between real-world health data and advertising to increase TV ad performance while prioritizing privacy. The company’s innovative solution comes as response to increased privacy regulations like My Health My Data and the implications these changes will have on health and pharmaceutical advertising. Inviting Taylor to advise and audit BranchLab’s methodology proves the company’s dedication and transparency to a fully compliant and privacy-safe solution for targeting consumers and healthcare professionals. 

Commenting on his appointment, Taylor said, “I am excited to join BranchLab’s Board of Advisors and look forward to contributing to the company’s growth and success. BranchLab’s innovative approach and dedication align with my own commitment to fostering progress in the biopharmaceutical sector. I look forward to seeing what the future holds for both BranchLab and the healthcare industry.” 

Taylor led Milbank’s biopharma patent practice from 2003 through 2020, serving as lead trial counsel in numerous multiparty, multinational cases involving some of the world’s most prescribed medicines. Taylor’s accomplishments have earned him recognition from numerous prestigious publications and journals, including Chambers USA, Managing IP, Benchmark Litigation, Super Lawyers, and IAM Magazine, which selected him as one of the top 250 IP lawyers in the world. In 2020, LMG Life Sciences nominated him as a finalist for “Hatch-Waxman Litigator of the Year,” and in 2018, Lawdragon honored him as one of the 500 Leading Lawyers in America. The National Law Journal recognized him as one of the nation’s top trial lawyers in 2003. 

“We are honored to welcome Errol, the preeminent expert in biopharmaceutical law, to BranchLab’s Board of Advisors,” said Josh Walsh, CEO of BranchLab. “Errol’s deep understanding of the complex legal landscape surrounding healthcare data is unparalleled. His guidance will be instrumental in ensuring that BranchLab remains at the forefront of privacy-safety while driving innovation in healthcare marketing. We believe that by incorporating Errol’s expertise, we are taking a significant step towards creating a future where patients can benefit from personalized healthcare without compromising their privacy.” 

Taylor joins BranchLab’s advisory board of distinguished leaders in the advertising, healthcare, and venture capital sectors including:  

  • Zachary Chapman: SVP, Global Partnerships, NBCUniversal 
  • Andy Fisher: Principal, Xaconagroup; Head of Merkury Advanced TV, Merkle
  • John Harlow: Chief Commercial Officer, Melinta Therapeutics
  • Paul Olliver: Managing Partner, Wider Wake
  • Ari Paparo: CEO, Marketecture Media; Co-Founder & Former CEO, Beeswax
  • Scott Russo: Founder and Managing Partner, Dasein Capital
  • Catherine Sullivan: President of Sales, Marketing & Partnerships, National CineMedia; Former CEO of PHD US

###

Read more on this exciting news via Broadcasting + Cable